By Admin 
Weight loss medicine: Sun Pharma’s new drug utriglutide, which is being developed to treat obesity and type-2 diabetes, has shown significant weight loss and metabolic improvements in post-menopausal women in early clinical studies. The results of the Phase 1a/2b trial of this drug were presented this week in the scientific session of the American Heart Association (AHA) held in New Orleans, USA. Utriglutide belongs to the same drug group as the world famous Monzaro and Vigovi. The specialty of these medicines is that they have become increasingly popular in India also. These medicines are GLP-1 receptor agonists, which work like liver hormones to reduce appetite.
What came out in the trial?
According to Sun Pharma, apart from weight loss, the drug showed improvement in several biomarkers related to systolic blood pressure, liver fat, and insulin sensitivity. Along with this, serum uric acid also reduced, which shows that the drug can affect many aspects of metabolic problems. Sun Pharma Chairman Dilip Shanghvi said, “Obesity and metabolic liver disease are on the rise, especially in post-menopausal women. The results of this initial study are encouraging and move us towards developing better treatments to combat these diseases.”
increasing problem
India’s anti-obesity drug market is currently worth Rs 3,000 to Rs 3,500 crore, which is expected to increase to Rs 25,000 crore by 2030. This was speculated to be due to the increasing problem of obesity and lifestyle diseases.
Study results give hope
This trial included post-menopausal women aged 52 to 69 years, who were suffering from obesity. After taking the drug for 14 weeks, those taking utriglutide lost an average of 8 percent weight and this continued until the 17th week. Those taking placebo lost only 2.1 percent and 1.2 percent weight, respectively.
What was seen till the 14th week?
- 76 percent women lost more than 5 percent weight.
- 25 percent women lost more than 10 percent weight.
- The average BMI initially was 43, which decreased to 39.7 to 39.8 by weeks 14 and 17.
The most important thing during this period was that there was a 28.6 percent reduction in liver fat, whereas only a 2.7 percent reduction was seen in the placebo group. These results show that this medicine can be helpful in problems like obesity as well as MASLD metabolic liver disease.
Side effect
If we talk about its side effects, they included loss of appetite, early fullness, nausea, indigestion and vomiting. Which are considered common among GLP-1 drugs. Dr. Rohit Loomba (UC San Diego), who was associated with the trial, said, “Utriglutide has shown significant improvement in liver fat and several metabolic parameters in women with obesity and MASLD, which is very encouraging.” If everything is approved after the trial, then this medicine can enter the market soon.
Read this also: World Diabetes Day 2025: Even if you don’t eat sweets, sugar level is increasing, know which habits increase the risk of diabetes?
Disclaimer: This information is based on research studies and expert opinion. Do not consider this as a substitute for medical advice. Before adopting any new activity or exercise, please consult your doctor or relevant specialist.
Check out below Health Tools-
Calculate Your Body Mass Index (BMI)
Calculate The Age Through Age Calculator